Trial Profile
Prospective, Randomized, Open-label Study With Blinded Endpoint (PROBE Design) to Compare the 72 hr Glycemic Profiles Obtained by Continuous Subcutaneous Glucose Monitoring (CSGM) in Type 2 Diabetic Patients at Baseline With Metformin Monotherapy and After an 8-week Period With the Addition of Either Vildagliptin or Sitagliptin in Patients Insufficiently Controlled by Metformin After at Least 3 Months of Monotherapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Vildagliptin (Primary) ; Metformin; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms OPTIMA
- Sponsors Novartis
- 01 Oct 2012 Results published in Diabetes and Metabolism.
- 03 May 2012 Actual patient number 36 added as reported by ClinicalTrials.gov.
- 03 May 2012 Actual end date Jun 2011 added as reported by ClinicalTrials.gov.